Phenylketonuria (PKU)

Abstract

Phenylketonuria (PKU) is one of the first characterised metabolic diseases. PKU is an autosomal recessive metabolic disorder resulting in increased phenylalanine concentrations. Without intervention, such as pharmaceutical or dietary restriction of phenylalanine, most children with PKU develop a profound and irreversible intellectual disability. In fact, this treatable condition is one of the leading causes of mental retardation. PKU can occur via two main mechanisms: classical and nonclassical. Classical PKU results from impaired activity of the liver enzyme phenylalanine hydroxylase, which converts phenylalanine to tyrosine. In nonclassical PKU, there is an absence or deficiency of dihydropteridine reductase which impairs the regeneration of tetrahydrobiopterin, a necessary cofactor in the conversion of phenylalanine to tyrosine. The advent of neonatal screening for PKU has enabled the start of a low‐phenylalanine diet early in life and thus, the prevention of intellectual retardation associated with the disease. The mainstay of treatment is a phenylalanine‐restricted diet, but its application varies both internationally and nationally.

Key Concepts

  • Phenylketonuria (PKU) is a rare metabolic disorder, characterised by an impaired ability to metabolise the amino acid phenylalanine and resultant high circulating levels of phenylalanine.
  • Classical PKU (the most common form) is caused by mutations in the gene for phenylalanine hydroxylase (PAH).
  • Nonclassical PKU can be caused by defects in the synthesis or function of the cofactor for PAH (BH4).
  • If not treated shortly after birth, PKU can be destructive to the nervous system, causing intellectual disability.
  • The identification of PKU during routine newborn screening and management with a diet low in phenylalanine became standard practice in the early 1960s.
  • PKU is a disorder that has an unequal geographic and ethnic distribution.
  • Individuals on well‐controlled phenylalanine‐free diet may still develop cognitive symptoms.
  • Several new therapies have recently emerged that provide alternatives to the strict low‐phenylalanine diet. A description of these treatments (medical foods, BH4 administration, large neutral amino acid supplementation and enzymatic therapy) is covered herein.

Keywords: PKU; metabolic disorder; hyperphenylalaninaemia; phenylalanine hydroxylase; inborn errors of metabolism; autosomal recessive; intellectual disability

Figure 1. Phenylalanine metabolism. Phenylalanine hydroxylase (PAH) catalyses the conversion of phenylalanine to tyrosine. Deficiencies in the activity of this enzyme result in incomplete phenylalanine metabolism and build‐up of toxic waste products. BH4, tetrahydrobiopterin; q‐BH2, quinonoid dihydrobiopterin; GTP, guanosine triphosphate.
Figure 2. Summary of potential mechanisms of neurocognitive impairment by hyperphenylalaninaemia. Excess phenylalanine competes with LNAA entry into the brain through LAT1. Phe indicates phenylalanine; BBB, blood–brain barrier; LNAA, large neutral amino acids; LAT1, large neutral amino acid carrier; BH4, tetrahydrobiopterin; Tyr, tyrosine; Trp, tryptophan.
Figure 3. Potential therapeutic approaches for phenylketonuria. Baby image reproduced from Shutterstock and is licensed under the Shutterstock Royalty‐Free License Agreement.
close

References

Andersen AE and Avins L (1976) Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria. Arch Neurol 33: 684–684.

Andrade R, Monteiro V, Cruz C, et al. (2015) Phenylalanine and tyrosine metabolism analysis in heterozygotes for phenylketonuria and in healthy individuals. Journal of Inborn Errors of Metabolism and Screening 3: 1–6.

Anastasoaie V, Kurzius L, Forbes P and Waisbren S (2008) Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Molecular Genetics and Metabolism 95 (1–2): 17–20.

Anjema K, Rijn MV, Hofstede FC, et al. (2013) Tetrahydrobiopterin responsiveness in phenylketonuria: prediction with the 48‐hour loading test and genotype. Orphanet Journal of Rare Diseases 8 (1): 103.

Blau N, van Spronsen FJ and Levy HL (2010) Phenylketonuria. Lancet 376 (9750): 1417–1427.

Bosch AM, Burlina A, Cunningham A, et al. (2015) Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet Journal of Rare Diseases 10 (1): 80–94.

Bremer HJ, Duran D, Kamerling JP, Przyrembel H and Wadman SK (eds) (1981) Disturbances of Amino Acid Metabolism: Clinical Chemistry and Diagnosis, pp. 307–327. Baltimore, MD: Urban & Schwarzenberg (Chapter on clinical chemistry and diagnosis of inherited diseases).

Burgard P, Rupp A, Konecki DS, et al. (1996) Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. European Journal of Pediatrics 155 (S1): S11–S15.

Christ SE (2003) Asbjörn Fölling and the discovery of phenylketonuria. Journal of the History of the Neurosciences 12 (1): 44–54.

Christ SE, Huijbregts SC, Sonneville LM and White DA (2010) Executive function in early‐treated phenylketonuria: profile and underlying mechanisms. Molecular Genetics and Metabolism 99 (Suppl 1): S22–S32.

Eisensmith RC and Woo SLC (1995) Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. Advances in Genetics 32: 199–271.

Feillet F and Agostoni C (2010) Nutritional issues in treating phenylketonuria. Journal of Inherited Metabolic Disease 33 (6): 659–664.

Feillet F, Spronsen FJ, Macdonald A, et al. (2010) Challenges and pitfalls in the management of phenylketonuria. Pediatrics 126 (2): 333–341.

Fang B, Eisensmith RC and Woo SL (1995) Phenylketonuria: a model for hepatic gene therapy. Mental Retardation and Developmental Disabilities Research Reviews 1 (1): 56–61.

Fernstrom JD (2012) Large neutral amino acids: dietary effects on brain neurochemistry and function. Amino Acids 45 (3): 419–430.

Fisch RO, Tsai MY and Gentry WC (1981) Studies of phenylketonurics with dermatitis. Journal of the American Academy of Dermatology 4 (3): 284–290.

Harding C (2008) Progress toward cell‐directed therapy for phenylketonuria. Clinical Genetics 74 (2): 97–104.

Hoang L, Byck S, Prevost L and Scriver CR (1996) PAH Mutation Analysis Consortium Database: a database for disease‐producing and other allelic variation at the human PAH locus. Nucleic Acids Research 24 (1): 127–131.

Jung S, Park J, Oh H, et al. (2008) Protective effect of recombinant adeno‐associated virus 2/8‐mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria. Journal of Korean Medical Science 23 (5): 877.

Kahler SG and Fahey MC (2003) Metabolic disorders and mental retardation. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics 117C (1): 31–41.

Kaufman S, Holtzman NA, Milstien S, Butler IJ and Krumholz A (1975) Phenylketonuria due to a deficiency of dihydropteridine reductase. New England Journal of Medicine 293 (16): 785–790.

Koura HM, Ismail NA, Kamel AF, et al. (2011) A long‐term study of bone mineral density in patients with phenylketonuria under diet therapy. Archives of Medical Science 3: 493–500.

LaClair CE, Ney DM, MacLeod EL and Etzel MR (2009) Purification and use of glycomacropeptide for nutritional management of phenylketonuria. Journal of Food Science 74 (4): E199–E206.

Nowacki PM, Byck S, Prevost L and Scriver CR (1997) The PAH mutation analysis consortium database update 1996. Nucleic Acids Research 25 (1): 139–142.

Patel D, Kopec J, Fitzpatrick F, Mccorvie TJ and Yue WW (2016) Structural basis for ligand‐dependent dimerization of phenylalanine hydroxylase regulatory domain. Scientific Reports 6: 23748. DOI: 10.1038/srep23748.

Pietz J, Dunckelmann R, Rupp A, et al. (1998) Neurological outcome in adult patients with early‐treated phenylketonuria. European Journal of Pediatrics 157 (10): 824–830.

Sarkissian CN, Gamez A, Wang L, et al. (2008) Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proceedings of the National Academy of Sciences 105 (52): 20894–20899.

Schlegel G, Scholz R, Ullrich K, Santer R and Rune GM (2016) Phenylketonuria: direct and indirect effects of phenylalanine. Experimental Neurology 281: 28–36.

Sharman R, Sullivan K, Young R and McGill J (2015) Executive function in adolescents with PKU and their siblings: associations with biochemistry. Molecular Genetics and Metabolism Reports 4: 87–88.

Spronsen FJ, Groot MJ, Hoeksma M, Reijngoud D and Rijn MV (2010) Large neutral amino acids in the treatment of PKU: from theory to practice. Journal of Inherited Metabolic Disease 33 (6): 671–676.

Spronsen FJ and Enns GM (2010) Future treatment strategies in phenylketonuria. Molecular Genetics and Metabolism 99 (Suppl 1): S90–S95.

Tavana S, Amini S, Hakhamaneshi MS, et al. (2016) Prooxidant‐antioxidant balance in patients with phenylketonuria and its correlation to biochemical and hematological parameters. Journal of Pediatric Endocrinology and Metabolism 29 (6): 675–680.

Vernon H (2012) Update on the treatment of phenylketonuria: long‐term safety and efficacy of sapropterin dihydrochloride. Research and Reports in Endocrine Disorders 2: 11–17.

Williams RA, Mamotte CD and Burnett JR (2008) Phenylketonuria: an inborn error of phenylalanine metabolism. Clinical Biochemistry Reviews 29: 31–41.

Yan S and Wu G (2008) Connecting mutant phenylalanine hydroxylase with phenylketonuria. Journal of Clinical Monitoring and Computing 22 (5): 333–342.

Further Reading

Albrecht J, Garbade SF and Burgard P (2009) Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta‐analysis. Neuroscience & Biobehavioral Reviews 33 (3): 414–421.

American Academy of Pediatrics (2001) Maternal phenylketonuria policy statement. Pediatrics 107 (2): 427–428.

Blau N (2016) Genetics of phenylketonuria: then and now. Human Mutation 37 (6): 508–515.

Eisensmith RC and Woo SL (1992) Molecular basis of phenylketonuria and related hyperphenylalaninemias: mutations and polymorphisms in the human phenylalanine hydroxylase gene. Human Mutation 1 (1): 13–23.

Feldmann R (2002) Phenylketonuria: no specific frontal lobe‐dependent neuropsychological deficits of early‐treated patients in comparison with diabetics. Pediatric Research 51 (6): 761–765.

Groselj U, Tansek MZ and Battelino T (2014) Fifty years of phenylketonuria newborn screening – a great success for many, but what about the rest? Molecular Genetics and Metabolism 113 (1–2): 8–10.

Kaufman S (1997) Tetrahydrobiopterin, pp. 262–322. Baltimore, MD: Johns Hopkins University Press (Chapter on phenylketonuria and its variants).

Mazur A, Jarochowicz S, Sykut‐Cegielska J, et al. (2010) Evaluation of somatic development in adult patients with previously undiagnosed and/or untreated phenylketonuria. Medical Principles and Practice 19 (1): 46–50.

Underhaug J, Aubi O and Martinez A (2013) Phenylalanine hydroxylase misfolding and pharmacological chaperones. Current Topics in Medicinal Chemistry 12 (22): 2534–2545.

Waisbren SE, Noel K, Fahrbach K, et al. (2007) Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta‐analysis. Molecular Genetics and Metabolism 92 (1–2): 63–70.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Gonzalez‐Lopez, Eugene, McFalls, Ashley J, and Vrana, Kent E(Nov 2016) Phenylketonuria (PKU). In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0002006.pub2]